Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 375

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Azithromycin for the Secondary Prevention of Coronary Events

Open access
Grayston, J. Thomas, Kronmal, Richard A., Jackson, Lisa A., Parisi, Alfred F., Muhlestein, Joseph B., Cohen, Jerome D., Rogers, William J., Crouse, John R., Borrowdale, Sandra L., Schron, Eleanor, Knirsch, Charles·2005·New England Journal of Medicine
DOI 10.1056/nejmoa043526
Open this paper in CoChat — free account

Abstract

BACKGROUND: Epidemiologic, laboratory, animal, and clinical studies suggest that there is an association between Chlamydia pneumoniae infection and atherogenesis. We evaluated the efficacy of one year of azithromycin treatment for the secondary prevention of coronary events. METHODS: In this randomized, prospective trial, we assigned 4012 patients with documented stable coronary artery disease to receive either 600 mg of azithromycin or placebo weekly for one year. The participants were followed for a mean of 3.9 years at 28 clinical centers throughout the United States. RESULTS: The primary end point, a composite of death due to coronary heart disease, nonfatal myocardial infarction, coronary revascularization, or hospitalization for unstable angina, occurred in 446 of the participants who had been randomly assigned to receive azithromycin and 449 of those who had been randomly assigned to receive placebo. There was no significant risk reduction in the azithromycin group as compared with the placebo group with regard to the primary end point (risk reduction, 1 percent [95 percent confidence interval, -13 to 13 percent]). There were also no significant risk reductions with regard to any of the components of the primary end point, death from any cause, or stroke. The results did not differ when the participants were stratified according to sex, age, smoking status, presence or absence of diabetes mellitus, or C. pneumoniae serologic status at baseline. CONCLUSIONS: A one-year course of weekly azithromycin did not alter the risk of cardiac events among patients with stable coronary artery disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa043526

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 5

  1. Biological mechanisms and animal models. In: Fong IW. Infections and the cardiovascular system: new perspectives. New York: Kluwer Academic/Plenum, 2003:144-9. · DOI
  2. 10.1086/321810 · doi:10.1086/321810
  3. 10.1086/315622 · doi:10.1086/315622
  4. 10.1093/clinids/24.1.76 · doi:10.1093/clinids/24.1.76
  5. 10.1128/AAC.46.8.2321-2326.2002 · doi:10.1128/aac.46.8.2321-2326.2002

Cited by

See all 375

Metadata

Authors
Grayston, J. T., Kronmal, R. A., Jackson, L. A., Parisi, A. F., Muhlestein, J. B., Cohen, J. D., Rogers, W. J., Crouse, J. R., Borrowdale, S. L., Schron, E., & Knirsch, C.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2005-04-21
Volume
352
Issue
16
Pages
1637-1645
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa043526
OpenAlex
W2386099697
Cited by
375
References
19
FWCI
37.35
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Azithromycin for the Secondary Prevention of Coronary Events. https://app.cochat.ai/papers/10.1056/nejmoa043526
The paper
Grayston, J. T., Kronmal, R. A., Jackson, L. A., Parisi, A. F., Muhlestein, J. B., Cohen, J. D., Rogers, W. J., Crouse, J. R., Borrowdale, S. L., Schron, E., & Knirsch, C. (2005). Azithromycin for the Secondary Prevention of Coronary Events. New England Journal of Medicine. https://doi.org/10.1056/nejmoa043526

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.